Skip to main content
Figure 1 | Journal of Neuroinflammation

Figure 1

From: Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer’s disease mouse model

Figure 1

Pharmacologic blockade of 5-lipoxygenase activating protein decreases brain Aβ peptides levels and deposition. (A-D) RIPA-soluble (RIPA) and formic acid extractable (FA) Aβ1-40 and Aβ1-42 levels in cortex and hippocampus of Tg2576 receiving MK-591 or placebo for 8 months were measured by sandwich ELISA. (n = 9 for control, and n = 11 for MK-591; *P <0.04). (E) Representative sections of brains from Tg2576 mice receiving MK-591 or placebo (control) for 8 months immunostained with 4 G8 antibody. (F) Quantification of the area occupied by Aβ immunoreactivity in brain of Tg2576 mice receiving MK-591 or placebo for 8 months (*P = 0.03). ELISA: enzyme-linked immunosorbent assay; FA: formic acid; RIPA: radioimmunoprecipitation assay.

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094